Oncology: The Race Is On In HRPC; Sponsors Of Niche Oncologics Struggle

Sanofi-Aventis expects to complete a rolling NDA submission for its "home grown" novel taxoid Jevtana (cabazitaxel) by the end of the first quarter, Sanofi-Aventis Global Operations President Hanspeter Spek told a Feb. 10 earning call.